Effect of HPV Vaccination on Virus Disappearance in Cervical Samples of a Cohort of HPV-Positive Polish Patients

The introduction of human papillomavirus vaccines revolutionized cervical cancer prevention. Our research hypothesis is that HPV vaccination affects the remission of HPV in cervical swabs. We provide a prospective, ongoing, 24-month, non-randomized study in HPV-positive women. We enrolled 60 patients with positive HPV swabs from the cervix (fifty-one vaccinated with the nine-valent vaccine against HPV and nine unvaccinated). Using an enzyme-linked immunosorbent assay, we determined IgG class antibodies of HPV in the patients’ serums. Persistent HPV infection after vaccination was significantly less frequent in the nine-valent vaccinated group (23.5%) compared to the control group (88.9%; p < 0.001). Antibody level after vaccination was significantly higher in the vaccinated patients compared to the control group. The reactive antibody level was seen in the case of all patients in the vaccinated group and one-third of the unvaccinated group (33.3%, n = 3). The vaccination of HPV-positive patients may increase the chance of HPV remission in cervical swabs and may be a worthwhile element of secondary prevention in HPV-positive patients.

[1]  R. Jach,et al.  Prevalence of HPV and Assessing Type-Specific HPV Testing in Cervical High-Grade Squamous Intraepithelial Lesions in Poland , 2023, Pathogens.

[2]  Yanmin Xu,et al.  Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives , 2022, Frontiers in Cellular and Infection Microbiology.

[3]  I. Zapardiel,et al.  Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study , 2022, Vaccines.

[4]  W. Tjalma,et al.  If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment? , 2021, European journal of obstetrics, gynecology, and reproductive biology.

[5]  M. Schiffman,et al.  Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. , 2021, Journal of lower genital tract disease.

[6]  M. Lehtinen,et al.  Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. , 2021, The Lancet. Infectious diseases.

[7]  E. Kontopantelis,et al.  Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis , 2021, Vaccines.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  G. Bogani,et al.  Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease , 2021, Vaccines.

[10]  A. Näsman,et al.  Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008–2018, and perspectives on cancer prevention , 2020, Archives of Gynecology and Obstetrics.

[11]  P. Hillemanns,et al.  Prophylactic HPV vaccination after conization: A systematic review and meta-analysis , 2020, Geburtshilfe und Frauenheilkunde.

[12]  Robert A. Goulart,et al.  Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories. , 2020, Journal of the American Society of Cytopathology.

[13]  A. Spathis,et al.  Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women , 2020, Cancers.

[14]  A. Rogers,et al.  Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis , 2020, International Journal of Gynecological Cancer.

[15]  K. Levinson,et al.  Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. , 2020, Obstetrics and gynecology.

[16]  M. Schiffman,et al.  2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2020, Journal of lower genital tract disease.

[17]  S. Kjaer,et al.  Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status , 2019, International journal of cancer.

[18]  J. Lew,et al.  The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. , 2019, Gynecologic oncology.

[19]  Hoon Choi Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study , 2019, International braz j urol : official journal of the Brazilian Society of Urology.

[20]  Sarah E. Stumbar,et al.  Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management. , 2019, Primary care.

[21]  C. Godballe,et al.  Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis , 2018, The Journal of infectious diseases.

[22]  H. Marshall,et al.  The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  F. Petraglia,et al.  Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease , 2018, Archives of Gynecology and Obstetrics.

[24]  J. Lew,et al.  Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. , 2018, Vaccine.

[25]  R. Rouzier,et al.  Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial. , 2018, Vaccine.

[26]  E. Rybicki,et al.  Therapeutic vaccines for high-risk HPV-associated diseases , 2017, Papillomavirus research.

[27]  S. Leeson,et al.  Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. , 2017, The Lancet. Oncology.

[28]  R. Winer,et al.  Natural History of HPV Infection across the Lifespan: Role of Viral Latency , 2017, Viruses.

[29]  M. Jit,et al.  Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. , 2017, Vaccine.

[30]  D. Harper,et al.  HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.

[31]  G. Ciccarese,et al.  Prevalence of genital, oral, and anal HPV infection among STI patients in Italy , 2017, Journal of medical virology.

[32]  M. Lehtinen,et al.  Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial , 2016, International journal of cancer.

[33]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[34]  O. Dillioglugil,et al.  Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study. , 2014, The journal of sexual medicine.

[35]  J. Didkowska,et al.  Nowotwory w Polsce w 2012 roku , 2013 .

[36]  Sun-Ouck Kim,et al.  Efficacy of the human papillomavirus vaccination in women aged 20-45 years with high-grade cervical intraepithelial neoplasia treated by loop electrosurgical excision procedure , 2013 .

[37]  D. Lowy,et al.  Understanding and learning from the success of prophylactic human papillomavirus vaccines , 2012, Nature Reviews Microbiology.

[38]  W. Kędzia,et al.  Assessment of frequency of regression and progression of mild cervical neoplasia--LGSIL in women with positive high-risk HPV DNA test result. , 2012, Ginekologia polska.

[39]  Daron G Ferris,et al.  Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data , 2012, BMJ : British Medical Journal.

[40]  J. Berkhof,et al.  Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. , 2011, The Lancet. Oncology.

[41]  H. Jessen,et al.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.

[42]  D. Lowy,et al.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.

[43]  H. Kitchener,et al.  Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer , 2007, Expert opinion on biological therapy.

[44]  G. Song,et al.  Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes , 2006, Archives of Virology.

[45]  Mark Marsh,et al.  Virus Entry: Open Sesame , 2006, Cell.

[46]  L. Pelkmans,et al.  Insider information: what viruses tell us about endocytosis. , 2003, Current opinion in cell biology.

[47]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[48]  M. Hagensee,et al.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.

[49]  Corey D. Fogleman,et al.  Prophylactic Vaccination Against Human Papillomavirus to Prevent Cervical Cancer and Its Precursors. , 2019, American family physician.

[50]  L. Dušek,et al.  The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[51]  C. Woodman,et al.  The natural history of cervical HPV infection: unresolved issues , 2007, Nature Reviews Cancer.

[52]  J. Higginson International agency for research on cancer. , 1974, Archives of pathology.